FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078167965> ?p ?o ?g. }

• W2078167965 endingPage "821" @default.
• W2078167965 startingPage "817" @default.
• W2078167965 abstract "Chronic myeloid leukemia (CML) is characterized by the BCR–ABL fusion protein produced as a result of the reciprocal translocation between a portion of the ABL tyrosine kinase gene on chromosome 9 and a region within the BCR gene on chromosome 22. The BCR–ABL oncoprotein displays constitutively elevated tyrosine kinase activity that drives the pathogenesis of CML by activating multiple signaling pathways including the RAS/MAPK, PI3K/AKT and JAK2/STAT5 pathways. The development of tyrosine kinase inhibitors (TKIs) aimed at BCR–ABL revolutionized the treatment of CML. Imatinib was the first of the TKIs to become available after it was approved by the US FDA in 2002 based upon data from the IRIS. Indeed, imatinib was associated with unprecedented rates of hematologic, cytogenetic and molecular responses in comparison with IFN-a with complete hematologic response (CHR) rates of 97%, complete cytogenetic response (CCyR) rates of 82% and major molecular response (MMR) rates on the international scale (IS) of 86% [1]. Treatment with imatinib also resulted in significantly improved rates of freedom from progression in comparison with IFN-a with an 8-year freedom from progression to accelerated or blast phase of 92% and afforded patients who were able to remain on treatment an 8-year overall survival (OS) of 85% [1]. However, imatinib use has been complicated by the development of resistance. Resistance led to 24% of patients in IRIS failing to achieve a CCyR at 18 months, which represented treatment failure [2]. Resistance also led 17% of patients on imatinib in IRIS to develop relapsed disease and 7% to develop progressive disease [2]. These numbers are, in fact, likely to be underestimates given the number of patients in the IRIS study who came off the trial and were not ultimately included in analysis. Treatment failure and disease progression due to resistance is also seen in patients treated with the subsequently approved second-generation TKIs, dasatinib, nilotinib and bosutinib. The etiology of resistance to TKIs is multifactorial and involves BCR–ABL independent and dependent mechanisms. Insufficient plasma levels of imatinib due to noncompliance, drug–drug interactions or binding to acute-phase inflammatory proteins can all result in resistance. It is known that trough plasma levels of imatinib are important for good clinical outcomes, and it has been demonstrated that patients with high imatinib exposure have better rates of CCyR, MMR and event-free survival [3]. Imatinib and all three of the second-generation TKIs are substrates for, and are extensively metabolized by, the cytochrome P450 enzymes including CYP3A4. As there are multiple drugs, food products and supplements that either induce or inhibit CYP3A4 activity, the potential for drug interactions is high. Alpha 1 acid glycoprotein has been identified as an acutephase inflammatory product that binds directly to imatinib and is frequently “As the number of drugs available for the treatment of chronic myeloid leukemia has expanded, so have the strategies for overcoming or avoiding resistance.”" @default.
• W2078167965 created "2016-06-24" @default.
• W2078167965 creator A5011529063 @default.
• W2078167965 creator A5019463496 @default.
• W2078167965 date "2013-09-01" @default.
• W2078167965 modified "2023-09-24" @default.
• W2078167965 title "Overcoming resistance in chronic myeloid leukemia" @default.
• W2078167965 cites W1966722003 @default.
• W2078167965 cites W1983852790 @default.
• W2078167965 cites W1993205583 @default.
• W2078167965 cites W1999614615 @default.
• W2078167965 cites W2037602803 @default.
• W2078167965 cites W2039531591 @default.
• W2078167965 cites W2052202516 @default.
• W2078167965 cites W2053131280 @default.
• W2078167965 cites W2055515709 @default.
• W2078167965 cites W2057206328 @default.
• W2078167965 cites W2072834954 @default.
• W2078167965 cites W2075786831 @default.
• W2078167965 cites W2100041900 @default.
• W2078167965 cites W2104694028 @default.
• W2078167965 cites W2107268345 @default.
• W2078167965 cites W2110648386 @default.
• W2078167965 cites W2113636726 @default.
• W2078167965 cites W2121533957 @default.
• W2078167965 cites W2149330162 @default.
• W2078167965 cites W2165142542 @default.
• W2078167965 cites W2172189430 @default.
• W2078167965 cites W2261840157 @default.
• W2078167965 cites W2271864214 @default.
• W2078167965 cites W2414725307 @default.
• W2078167965 cites W2552922406 @default.
• W2078167965 cites W2560510265 @default.
• W2078167965 cites W2574923075 @default.
• W2078167965 doi "https://doi.org/10.4155/cli.13.75" @default.
• W2078167965 hasPublicationYear "2013" @default.
• W2078167965 type Work @default.
• W2078167965 sameAs 2078167965 @default.
• W2078167965 citedByCount "0" @default.
• W2078167965 crossrefType "journal-article" @default.
• W2078167965 hasAuthorship W2078167965A5011529063 @default.
• W2078167965 hasAuthorship W2078167965A5019463496 @default.
• W2078167965 hasConcept C104317684 @default.
• W2078167965 hasConcept C121608353 @default.
• W2078167965 hasConcept C125418893 @default.
• W2078167965 hasConcept C126322002 @default.
• W2078167965 hasConcept C138626823 @default.
• W2078167965 hasConcept C170493617 @default.
• W2078167965 hasConcept C203014093 @default.
• W2078167965 hasConcept C2777583451 @default.
• W2078167965 hasConcept C2778208673 @default.
• W2078167965 hasConcept C2778729363 @default.
• W2078167965 hasConcept C2778820342 @default.
• W2078167965 hasConcept C2778904597 @default.
• W2078167965 hasConcept C2779536868 @default.
• W2078167965 hasConcept C3019892230 @default.
• W2078167965 hasConcept C42362537 @default.
• W2078167965 hasConcept C43907098 @default.
• W2078167965 hasConcept C502942594 @default.
• W2078167965 hasConcept C54355233 @default.
• W2078167965 hasConcept C71924100 @default.
• W2078167965 hasConcept C86803240 @default.
• W2078167965 hasConceptScore W2078167965C104317684 @default.
• W2078167965 hasConceptScore W2078167965C121608353 @default.
• W2078167965 hasConceptScore W2078167965C125418893 @default.
• W2078167965 hasConceptScore W2078167965C126322002 @default.
• W2078167965 hasConceptScore W2078167965C138626823 @default.
• W2078167965 hasConceptScore W2078167965C170493617 @default.
• W2078167965 hasConceptScore W2078167965C203014093 @default.
• W2078167965 hasConceptScore W2078167965C2777583451 @default.
• W2078167965 hasConceptScore W2078167965C2778208673 @default.
• W2078167965 hasConceptScore W2078167965C2778729363 @default.
• W2078167965 hasConceptScore W2078167965C2778820342 @default.
• W2078167965 hasConceptScore W2078167965C2778904597 @default.
• W2078167965 hasConceptScore W2078167965C2779536868 @default.
• W2078167965 hasConceptScore W2078167965C3019892230 @default.
• W2078167965 hasConceptScore W2078167965C42362537 @default.
• W2078167965 hasConceptScore W2078167965C43907098 @default.
• W2078167965 hasConceptScore W2078167965C502942594 @default.
• W2078167965 hasConceptScore W2078167965C54355233 @default.
• W2078167965 hasConceptScore W2078167965C71924100 @default.
• W2078167965 hasConceptScore W2078167965C86803240 @default.
• W2078167965 hasIssue "9" @default.
• W2078167965 hasLocation W20781679651 @default.
• W2078167965 hasOpenAccess W2078167965 @default.
• W2078167965 hasPrimaryLocation W20781679651 @default.
• W2078167965 hasRelatedWork W1921338684 @default.
• W2078167965 hasRelatedWork W1922676200 @default.
• W2078167965 hasRelatedWork W2019199342 @default.
• W2078167965 hasRelatedWork W2030154801 @default.
• W2078167965 hasRelatedWork W2060684847 @default.
• W2078167965 hasRelatedWork W2078167965 @default.
• W2078167965 hasRelatedWork W2155107050 @default.
• W2078167965 hasRelatedWork W2188003467 @default.
• W2078167965 hasRelatedWork W3006090897 @default.
• W2078167965 hasRelatedWork W3189565403 @default.
• W2078167965 hasVolume "3" @default.
• W2078167965 isParatext "false" @default.

• next